Table 1:
Demographics of the study population and the number of GBCA administrations
| Healthy Controls | Linear MS Group | Mixed MS Group | Macrocyclic MS Group | |
|---|---|---|---|---|
| Participants (No.) | 21 | 11 | 59 | 15 |
| Male/female ratio | 10:11 | 3:8 | 18:41 | 4:11 |
| Age (mean) (yr) | 35.9 ± 13.8 | 51.0 ± 10.7 | 43.8 ± 10.3 | 37.4 ± 13.7 |
| MS duration (mean) (yr) | NA | 19.8 ± 9.3 | 12.9 ± 8.1 | 5.1 ± 6.0 |
| MS subtype, RR/SP/PP | NA | 5/6/0 | 39/17/3 | 14/1/0 |
| EDSS score (median) (range) | NA | 2.5 (0–6); n = 11 | 2 (08.5); n = 54 | 2 (1–4); n = 13 |
| SDMT score (median) (range) | NA | −0.19 (−1.47–0.84); n = 5 | −1.1 (−3.9–1.4); n = 36 | −1.3 (−4.3–0.51); n = 12 |
| Verbal fluency test score (median) (range) | NA | 0.74 (−1.82–.36); n = 4 | −0.24 (−2.47–2.17); n= 17 | −1.32 (−2.94–.04); n = 6 |
| MS lesion volume (median ± interquartile range) (mL) | NA | 5.1 ± 10.1 | 3.1 ± 9.2 | 2.4 ± 4.2 |
| Brain parenchymal fraction (%) | 88.0 ± 2.4 | 79.6 ± 4.9 | 82.7 ± 5.9 | 84.6 ± 5.0 |
| Linear GBCA administrations (No.) (median) (range) | 0 | 3 (1–7) | 4 (1–19) | 0 (0) |
| Macrocyclic GBCA administrations (No.) (median) (range) | 0 | 0 | 2 (1–4) | 3 (1–6) |
| Time since last GBCA administration (median) (range) (mo) | NA | 52 (24–172) | 12 (3–91) | 7 (3–14) |
Note:—PP indicates primary-progressive; RR, relapsing-remitting; SP, secondary-progressive; NA, not applicable.
a
Numbers are given as means unless otherwise specified.